Clinical Trial Update: Combination of Olaparib and Navitoclax in Women with HGSC and TNBC [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the combination of olaparib and navitoclax in women with high-grade serous ovarian cancer and triple-negative breast cancer …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Serous Ovarian Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Lynparza (olaparib)
• Navitoclax (navitoclax)

Snippet

Sponsor: Sunnybrook Health Sciences Centre | Conditions: High Grade Serous Carcinoma, Triple Negative Breast Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING